Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of camrelizumab in advanced lung cancer
ChiCTR2100048607Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in bronchial carcinoma, sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Immune inspection index. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2100048607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048607.